The University of Chicago Header Logo

Connection

Marina Chiara Garassino to Retrospective Studies

Back to Details
This is a "connection" page, showing publications Marina Chiara Garassino has written about Retrospective Studies.
Marina Chiara Garassino
Connection Strength
0.668
Retrospective Studies
  1. Patient-reported outcomes with durvalumab by PD-L1 expression and prior chemoradiotherapy-related variables in unresectable stage III non-small-cell lung cancer. Future Oncol. 2021 Apr; 17(10):1165-1184.
    View in: PubMed
    Score: 0.075
  2. Outcomes of small-cell lung cancer patients treated with second-line chemotherapy: a multi-institutional retrospective analysis. Lung Cancer. 2011 Jun; 72(3):378-83.
    View in: PubMed
    Score: 0.037
  3. High bone tumor burden to identify advanced non-small cell lung cancer patients with survival benefit upon bone targeted agents and immune checkpoint inhibitors. Lung Cancer. 2023 12; 186:107417.
    View in: PubMed
    Score: 0.023
  4. Exploring the Role of Immunotherapy-Based Treatments for Advanced Non-Small-Cell Lung Cancer With Novel Driver Alterations. Clin Lung Cancer. 2023 11; 24(7):631-640.e2.
    View in: PubMed
    Score: 0.022
  5. The EU-funded I3LUNG Project: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy. Clin Lung Cancer. 2023 06; 24(4):381-387.
    View in: PubMed
    Score: 0.022
  6. Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study. J Thorac Oncol. 2023 02; 18(2):181-193.
    View in: PubMed
    Score: 0.021
  7. Autoantibody positivity predicts severity of rheumatic immune-related adverse events to immune-checkpoint inhibitors. Eur J Intern Med. 2022 09; 103:95-99.
    View in: PubMed
    Score: 0.021
  8. Prognostic role of neutrophil-to-lymphocyte ratio and EPSILoN score in advanced non-small-cell lung cancer patients treated with first-line chemo-immunotherapy. Future Oncol. 2022 Jul; 18(23):2593-2604.
    View in: PubMed
    Score: 0.021
  9. Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice. Clin Cancer Res. 2022 03 15; 28(6):1117-1126.
    View in: PubMed
    Score: 0.020
  10. A Definitive Prognostication System for Patients With Thoracic Malignancies Diagnosed With Coronavirus Disease 2019: An Update From the TERAVOLT Registry. J Thorac Oncol. 2022 05; 17(5):661-674.
    View in: PubMed
    Score: 0.020
  11. Outcomes With Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With NSCLC and Stable Brain Metastases: Pooled Analysis of KEYNOTE-021, -189, and -407. J Thorac Oncol. 2021 11; 16(11):1883-1892.
    View in: PubMed
    Score: 0.019
  12. Immune-Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer With Uncommon Histology. Clin Lung Cancer. 2022 01; 23(1):e17-e28.
    View in: PubMed
    Score: 0.019
  13. Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancer. Lung Cancer. 2021 07; 157:9-16.
    View in: PubMed
    Score: 0.019
  14. Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy. Eur J Cancer. 2021 06; 150:224-231.
    View in: PubMed
    Score: 0.019
  15. LKB1 Down-Modulation by miR-17 Identifies Patients With NSCLC Having Worse Prognosis Eligible for Energy-Stress-Based Treatments. J Thorac Oncol. 2021 08; 16(8):1298-1311.
    View in: PubMed
    Score: 0.019
  16. Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy. J Immunother Cancer. 2021 04; 9(4).
    View in: PubMed
    Score: 0.019
  17. Immunotherapy in advanced Non-Small Cell Lung Cancer patients with poor performance status: The role of clinical-pathological variables and inflammatory biomarkers. Lung Cancer. 2021 02; 152:165-173.
    View in: PubMed
    Score: 0.019
  18. Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study. Lung Cancer. 2020 12; 150:123-131.
    View in: PubMed
    Score: 0.018
  19. Impact of performance status on non-small-cell lung cancer patients with a PD-L1 tumour proportion score =50% treated with front-line pembrolizumab. Acta Oncol. 2020 Sep; 59(9):1058-1063.
    View in: PubMed
    Score: 0.018
  20. Accuracy of pathologic diagnosis for thymic epithelial tumors: a brief report from an Italian reference Center. Lung Cancer. 2020 08; 146:66-69.
    View in: PubMed
    Score: 0.018
  21. First-line pembrolizumab in advanced non-small cell lung cancer patients with poor performance status. Eur J Cancer. 2020 05; 130:155-167.
    View in: PubMed
    Score: 0.018
  22. DiM: Prognostic Score for Second- or Further-line Immunotherapy in Advanced Non-Small-Cell Lung Cancer: An External Validation. Clin Lung Cancer. 2020 09; 21(5):e337-e348.
    View in: PubMed
    Score: 0.018
  23. Incidence of T790M in Patients With NSCLC Progressed to Gefitinib, Erlotinib, and Afatinib: A Study on Circulating Cell-free DNA. Clin Lung Cancer. 2020 05; 21(3):232-237.
    View in: PubMed
    Score: 0.017
  24. Outpatient palliative care and thoracic medical oncology: Referral criteria and clinical care pathways. Lung Cancer. 2020 01; 139:13-17.
    View in: PubMed
    Score: 0.017
  25. Efficacy and safety of immunotherapy in elderly patients with non-small cell lung cancer. Lung Cancer. 2019 11; 137:38-42.
    View in: PubMed
    Score: 0.017
  26. Characterization of patients with metastatic non-small-cell lung cancer obtaining long-term benefit from immunotherapy. Future Oncol. 2019 Aug; 15(23):2743-2757.
    View in: PubMed
    Score: 0.017
  27. Metformin Enhances Cisplatin-Induced Apoptosis and Prevents Resistance to Cisplatin in Co-mutated KRAS/LKB1 NSCLC. J Thorac Oncol. 2018 11; 13(11):1692-1704.
    View in: PubMed
    Score: 0.016
  28. ALK gene copy number gains in non-small-cell lung cancer: prognostic impact and clinico-pathological correlations. Respir Res. 2016 08 25; 17(1):105.
    View in: PubMed
    Score: 0.014
  29. Does surgery improve survival of patients with malignant pleural mesothelioma?: a multicenter retrospective analysis of 1365 consecutive patients. J Thorac Oncol. 2014 Mar; 9(3):390-6.
    View in: PubMed
    Score: 0.012
  30. Male breast cancer: clinical features and multimodal treatment in a retrospective survey analysis at Italian centers. Tumori. 2013 Sep-Oct; 99(5):596-600.
    View in: PubMed
    Score: 0.011
  31. Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey. Lung Cancer. 2012 Mar; 75(3):360-7.
    View in: PubMed
    Score: 0.010
  32. Clinical and molecular determinants of survival in pancreatic cancer patients treated with second-line chemotherapy: results of an Italian/Swiss multicenter survey. Anticancer Res. 2010 Oct; 30(10):4289-95.
    View in: PubMed
    Score: 0.009
  33. Cetuximab for metastatic colorectal cancer. N Engl J Med. 2009 Jul 02; 361(1):95; author reply 96-7.
    View in: PubMed
    Score: 0.008
  34. Osteonecrosis of the jaw (ONJ) in cancer patients treated with Bisphosphonates: how the knowledge of a phenomenon can change its evolution. Support Care Cancer. 2008 Nov; 16(11):1311-5.
    View in: PubMed
    Score: 0.008
  35. An oxaliplatin + 5-fluorouracil bolus + folinic acid (BFOL) regimen as first-line treatment in metastatic colorectal cancer patients. Tumori. 2007 Nov-Dec; 93(6):557-61.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.